Summary of Significant Accounting Policies - Segment Information (Details) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2017 USD ($)	Mar. 31, 2016 USD ($)	Mar. 31, 2017 USD ($) segment	Mar. 31, 2016 USD ($)
Medical Indication Information
Contract manufacturing revenue	$ 2,178	$ 10,111	$ 15,266	$ 12,382
Net sales	165,720	163,712	498,223	397,204
Settlement agreement	(4,000)	(23,598)	(4,000)	(23,598)
Total net sales	161,720	140,114	$ 494,223	373,606
Segment information
Number of Reportable Segments | segment			1
Antibiotic
Medical Indication Information
Net sales	4,474	3,160	$ 13,047	8,716
Anti Psychosis
Medical Indication Information
Net sales	14,433	1,061	47,119	4,533
Cardiovascular
Medical Indication Information
Net sales	14,815	16,652	39,484	38,059
Central Nervous System
Medical Indication Information
Net sales	11,124	14,264	32,028	20,351
Gallstone
Medical Indication Information
Net sales	11,157	14,698	37,465	53,389
Gastrointestinal
Medical Indication Information
Net sales	19,441	21,739	56,470	30,431
Glaucoma
Medical Indication Information
Net sales	4,868	6,006	15,962	19,371
Migraine
Medical Indication Information
Net sales	7,043	5,090	22,066	16,338
Muscle Relaxant
Medical Indication Information
Net sales	3,673	1,193	10,208	4,246
Obesity
Medical Indication Information
Net sales	1,024	1,023	2,819	2,853
Pain Management
Medical Indication Information
Net sales	6,085	7,178	20,132	23,386
Respiratory
Medical Indication Information
Net sales	4,256	5,308	9,426	6,703
Thyroid Deficiency
Medical Indication Information
Net sales	44,999	38,009	130,267	116,543
Urinary
Medical Indication Information
Net sales	2,619	6,506	12,413	10,148
Other
Medical Indication Information
Net sales	$ 13,531	$ 11,714	$ 34,051	$ 29,755